Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2016-03-22 Delisting Announcement
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
KARO PHARMA AB (f.d. KARO BIO) HAR 99,4 PROCENT AV AKTIER OCH RÖSTER I MEDCORE OCH BEGÄR NU TVÅNGSINLÖSEN AV RESTERANDE AKTIER
Delisting Announcement Classification · 99% confidence The document is a press release dated March 22, 2016, announcing that Karo Pharma AB has acquired 99.4% of the shares in MedCore AB and is initiating compulsory redemption (tvångsinlösen) of the remaining shares. It also mentions the subsequent delisting of MedCore's shares. This action—a takeover/acquisition leading to compulsory redemption and delisting—falls under the scope of M&A activity or significant corporate transactions. Given the specific definitions, 'M&A Activity (Code: TAR)' is the most appropriate classification as it covers merger proposals or takeover bids, which this compulsory redemption process stems from. The document is a direct announcement of the transaction outcome, not just an announcement of a report.
2016-03-22 Swedish
Beslut vid Karo Bios extra bolagsstämma den 16 mars 2016
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) dated March 16, 2016, detailing the decisions made at Karo Bio's Extraordinary General Meeting (EGM) held on the same day. The key decisions involve approving a rights issue (nyemission) of approximately 250 MSEK and a resolution to change the company's articles of association (bolagsordningen), including a name change. Since the document reports the outcomes of a shareholder vote and major corporate actions decided at a general meeting, it strongly aligns with the scope of an AGM/EGM outcome announcement. Although it's an EGM, the closest category covering meeting outcomes and related corporate governance changes is AGM-R (AGM Information), which covers presentations and materials shared during the Annual General Meeting (implying general meeting outcomes). Given the focus on voting results and corporate structure changes decided by shareholders, AGM-R is the most appropriate fit among the provided options, rather than a general Regulatory Filing (RNS) or a specific Capital/Financing Update (CAP), as the context is the meeting itself.
2016-03-16 Swedish
KARO BIO RIKTAR KONTANTERBJUDANDE TILL MEDCORES AKTIEÄGARE
M&A Activity Classification · 98% confidence The document is a press release dated February 25, 2016, announcing that Karo Bio AB is making a cash offer (kontanterbjudande) to the shareholders of MedCore AB to acquire the remaining shares. This clearly describes a takeover bid or merger activity. Based on the definitions, this falls under M&A Activity (TAR). Although it is a press release, the core subject matter is the takeover bid itself, not just the announcement of a report (RPA) or a general regulatory filing (RNS). The text details the offer price, timeline, and intent for compulsory redemption and delisting, which are integral parts of a takeover process.
2016-02-25 Swedish
Interim / Quarterly Report 2015
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end Report) for the fiscal year 2015. It contains comprehensive financial statements, including income statements, cash flow data, and balance sheet information for the full year and the fourth quarter. It also includes management commentary, details on acquisitions, and forward-looking statements. As it provides substantive financial data for a period shorter than a full annual report (or as a preliminary year-end financial summary), it is classified as an Interim/Quarterly Report (IR). Q4 2015
2016-02-12 Swedish
Interim / Quarterly Report 2015
Interim / Quarterly Report Classification · 95% confidence The document is a 'Year-End Report' for 2015, which functions as a comprehensive financial report for a period shorter than a full fiscal year (or specifically the final quarter/year-end summary). It contains detailed financial statements, including income statements, cash flow data, and balance sheet information, as well as management commentary on operations, acquisitions, and future outlook. It is not an announcement of a report (RPA) because it contains the actual financial data, nor is it a full 10-K annual report, but rather an interim/year-end financial disclosure. FY 2015
2016-02-12 English
KARO BIO CARRIES OUT A FULLY GUARANTEED RIGHTS ISSUE OF MSEK 250
Capital/Financing Update Classification · 98% confidence The document is a press release announcing a fully guaranteed rights issue of MSEK 250 by Karo Bio AB. It details the terms of the issue (subscription price, ratio, record date), mentions an Extraordinary General Meeting to approve the resolution, and provides a preliminary timetable which includes the planned publication date for the prospectus. The core subject is a significant capital raising/financing activity. This aligns directly with the definition for 'Capital/Financing Update' (CAP). It is not a full 10-K, an ER, or an IR, but a specific announcement about raising capital.
2016-02-12 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.